☰

Eliza Vakana, Ph.D. - Publications

Affiliations: 
2013 Integrated Graduate Program in the Life Sciences Northwestern University, Evanston, IL 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Falchetti ML, D'Alessandris QG, Pacioni S, Buccarelli M, Morgante L, Giannetti S, Lulli V, Martini M, Larocca LM, Vakana E, Stancato L, Ricci-Vitiani L, Pallini R. Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1. International Journal of Cancer. PMID 30414187 DOI: 10.1002/Ijc.31983  0.373
2016 Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Oncotarget. PMID 27999210 DOI: 10.18632/Oncotarget.14002  0.486
2015 Tate CM, Mc Entire J, Pallini R, Vakana E, Wyss L, Blosser W, Ricci-Vitiani L, D'Alessandris QG, Morgante L, Giannetti S, Larocca LM, Todaro M, Benfante A, Colorito ML, Stassi G, et al. A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology. Plos One. 10: e0125697. PMID 25919028 DOI: 10.1371/Journal.Pone.0125697  0.42
2014 Blosser W, Vakana E, Wyss LV, Swearingen ML, Stewart J, Stancato L, Tate CM. A method to assess target gene involvement in angiogenesis in vitro and in vivo using lentiviral vectors expressing shRNA. Plos One. 9: e96036. PMID 24759702 DOI: 10.1371/Journal.Pone.0096036  0.377
2013 Vakana E, Arslan AD, Szilard A, Altman JK, Platanias LC. Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells. Plos One. 8: e78780. PMID 24260131 DOI: 10.1371/Journal.Pone.0078780  0.7
2013 Altman JK, Szilard A, Konicek BW, Iversen PW, Kroczynska B, Glaser H, Sassano A, Vakana E, Graff JR, Platanias LC. Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. Blood. 121: 3675-81. PMID 23509154 DOI: 10.1182/Blood-2013-01-477216  0.634
2013 Galvin JP, Altman JK, Szilard A, Goussetis DJ, Vakana E, Sassano A, Platanias LC. Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses. Cancer Biology & Therapy. 14: 411-6. PMID 23377826 DOI: 10.4161/Cbt.23760  0.69
2013 Tate C, McEntire J, Pallini R, Wyss L, Blosser W, Vakana E, D'Alessandris G, Morgante L, Giannetti S, Larocca L, Stassi G, Benfante A, Colorito M, Maria RD, Rowlinson S, et al. Abstract B5: A BMP7 variant inhibits angiogenesis in vitro and in vivo in part by downregulating VEGFR2 and FGFR1 expression in endothelial cells. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B5  0.461
2012 Goussetis DJ, Gounaris E, Wu EJ, Vakana E, Sharma B, Bogyo M, Altman JK, Platanias LC. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood. 120: 3555-62. PMID 22898604 DOI: 10.1182/Blood-2012-01-402578  0.685
2012 Vakana E, Altman JK, Platanias LC. Targeting AMPK in the treatment of malignancies. Journal of Cellular Biochemistry. 113: 404-9. PMID 21928327 DOI: 10.1002/Jcb.23369  0.631
2012 Goussetis D, Gounaris E, Wu EJ, Vakana E, Sharma B, Altman JK, Platanais LC, Bogyo M. Abstract LB-81: Autophagic degradation of BCR/ABL by arsenic trioxide and the role of cysteine cathepsins Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-81  0.693
2011 Vakana E, Platanias LC. AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. Oncotarget. 2: 1322-8. PMID 22249159 DOI: 10.18632/Oncotarget.413  0.688
2011 Vakana E, Altman JK, Glaser H, Donato NJ, Platanias LC. Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood. 118: 6399-402. PMID 22021366 DOI: 10.1182/Blood-2011-01-332783  0.704
2011 Redig AJ, Vakana E, Platanias LC. Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL. Leukemia & Lymphoma. 52: 45-53. PMID 21299459 DOI: 10.3109/10428194.2010.546919  0.706
2010 Vakana E, Sassano A, Platanias LC. Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells. Autophagy. 6: 966-7. PMID 20699667 DOI: 10.1073/Pnas.1005114107  0.706
2010 Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H, Druker BJ, Donato NJ, Altman JK, Barr S, Platanias LC. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proceedings of the National Academy of Sciences of the United States of America. 107: 12469-74. PMID 20616057 DOI: 10.1073/pnas.1005114107  0.655
2010 Vakana E, Platanias LC. PS3-15 Anti-leukemic effects of the AMPK activators AICAR and metformin in BCR-ABL expressing cells Cytokine. 52: 85. DOI: 10.1016/J.Cyto.2010.07.354  0.576
Show low-probability matches.